The last 3 years have seen the emergence of promising targeted therapies for the treatment
of hepatocellular carcinoma (HCC). Sorafenib has been the mainstay of treatment for a …

Hepatocellular carcinoma (HCC) is the most common form of primary liver cancer.
Sorafenib, regorafenib, lenvatinib and cabozantinib are tyrosine kinase inhibitors (TKIs) that …

Background & Aims Sorafenib, an oral multikinase inhibitor, significantly prolonged overall
survival (OS) vs. placebo in patients with unresectable hepatocellular carcinoma (HCC) in …

Hepatocellular carcinoma (HCC) is an aggressive malignancy, resulting as the third cause
of death by cancer each year. The management of patients with HCC is complex, as both the …

Background: Patients with advanced hepatocellular carcinoma (HCC) have a poor
prognosis. First-line sorafenib has been the standard of care for a decade, but the treatment …

We sought to investigate the clinical profile (s) associated with the discontinuation of
lenvatinib (LEN) due to severe adverse events (DLSAE) in patients with unresectable …

Background Sorafenib has demonstrated survival benefit in first-line treatment of advanced
hepatocellular carcinoma (HCC); utility of sorafenib in patients with advanced HCC and …

Background Since sorafenib has shown activity in different tumour types and gemcitabine
regimens improved the outcome for biliary tract cancer (BTC) patients, we evaluated first-line …

Sorafenib is the standard treatment for patients with hepatocellular carcinoma (HCC) with
advanced stage disease. Although its effectiveness has been demonstrated by randomized …

Background We aimed to evaluate the safety, efficacy and prognostic impact of baseline and
early clinical markers in both Child–Pugh A and B patients with advanced hepatocellular …